- A meta-analysis of vitamin D supplementation studies reports an odds ratio of 0.85 for cardiovascular events with a 95% confidence interval of (0.72, 1.01). A health policy committee is deciding whether to recommend vitamin D supplementation based on this evidence. Which statement best describes the appropriate interpretation?
Answer: The evidence is inconclusive for policy recommendations since the interval includes the null value
Since the 95% CI includes 1.0 (the null value for odds ratios), we cannot conclude statistical significance at α=0.05. This makes the evidence inconclusive for strong policy recommendations. Choice A ignores the statistical uncertainty. Choice C misinterprets inclusion of the null as evidence of harm. Choice D incorrectly quantifies the evidence based on the proportion of the interval below 1.0.
- A randomized controlled trial examined the effect of a new antihypertensive medication on systolic blood pressure reduction. The study reported a mean reduction of 12 mmHg with a 95% confidence interval of (8.2, 15.8) mmHg. If the same study had been conducted with a sample size four times larger while maintaining the same standard deviation, what would be the approximate width of the new 95% confidence interval?
Answer: 3.8 mmHg, because the margin of error decreases by half when sample size quadruples
The original CI width is 15.8 - 8.2 = 7.6 mmHg. When sample size increases by a factor of 4, the standard error decreases by √4 = 2, so the margin of error (and CI width) decreases by half. New width = 7.6/2 = 3.8 mmHg. Choice B incorrectly assumes direct inverse proportionality. Choice C confuses the relationship with variance. Choice D incorrectly suggests larger samples give wider intervals.
- Two independent studies examined the same treatment effect. Study 1 reported a mean difference of 5.2 units (95% CI: 1.8, 8.6). Study 2 reported a mean difference of 3.1 units (95% CI: 0.4, 5.8). A researcher claims these results are inconsistent because the point estimates differ by 2.1 units. What is the most appropriate response to this claim?
Answer: The claim is incorrect since the confidence intervals overlap substantially, suggesting compatible results
When evaluating consistency between studies, you need to assess whether the results are statistically compatible, not just whether the point estimates are identical. The key insight is that confidence intervals represent the range of plausible values for the true effect, and overlapping intervals suggest the studies could be measuring the same underlying phenomenon.
Study 1's 95% CI of (1.8, 8.6) and Study 2's 95% CI of (0.4, 5.8) overlap substantially from 1.8 to 5.8 units. This extensive overlap indicates the studies are statistically compatible despite having different point estimates (5.2 vs 3.1). The difference in point estimates simply reflects normal sampling variability between studies.
Option A is wrong because there's no rule that differences exceeding one standard error indicate inconsistency—you must examine the confidence intervals themselves. Option B misses the point entirely; while both intervals exclude zero (showing statistical significance), this doesn't address whether the studies are consistent with each other. Option C incorrectly focuses on the intervals' bounds rather than their overlap—the fact that Study 1's interval extends beyond Study 2's at both ends doesn't matter when there's substantial overlap in the middle.
The correct answer is D because the overlapping confidence intervals demonstrate that both studies are compatible with a range of true effect sizes, making them statistically consistent despite different point estimates.
Remember: When comparing studies, focus on confidence interval overlap, not just point estimate differences. Overlapping intervals typically indicate compatible results, while non-overlapping intervals suggest potential inconsistency.
- A cohort study reports the relative risk of lung cancer for smokers versus non-smokers as 8.5 with a 95% confidence interval of (6.2, 11.6). A second analysis adjusted for age and gender yields RR = 7.8 with 95% CI of (5.9, 10.3). What is the most appropriate interpretation of these results?
Answer: Age and gender are modest confounders since adjustment reduced the point estimate but maintained significance
The decrease from RR=8.5 to RR=7.8 after adjusting for age and gender suggests these variables were confounding the association, but the effect remains strong and significant. The confounding is modest because the change is relatively small. Choice A misinterprets interval width. Choice C incorrectly prefers unadjusted results. Choice D ignores the meaningful change in point estimates.
- A clinical trial comparing two pain medications found that Drug A reduced pain scores by a mean of 3.2 points more than Drug B, with a 95% confidence interval of (1.1, 5.3) points. The minimal clinically important difference (MCID) for this pain scale is 2.0 points. How should this result be interpreted regarding clinical significance?
Answer: The result is statistically significant but clinically uncertain since part of the interval falls below the MCID
The CI (1.1, 5.3) excludes 0, indicating statistical significance. However, since the lower bound (1.1) is below the MCID (2.0), we cannot be confident the true effect reaches clinical significance. Choice A is wrong because the entire interval does not exceed the MCID. Choice C misunderstands statistical significance. Choice D incorrectly claims no statistical significance.
- Two studies examined the same research question about mean hospital length of stay. Study A (n=100) reported a 95% CI of (4.2, 6.8) days. Study B (n=400) reported a 95% CI of (4.9, 5.7) days. Assuming both studies sampled from populations with identical means and standard deviations, which statement best explains the difference in interval widths?
Answer: Study B has a narrower interval due to reduced sampling variability from the larger sample size
With identical population parameters, the difference in CI width is due to sample size. Study B's larger sample (n=400 vs n=100) reduces the standard error by √(400/100) = 2, creating a narrower interval. Choice B is incorrect since both used 95% CI. Choice C contradicts the given assumption of identical populations. Choice D confuses bias with precision - smaller samples affect precision, not bias.
- A health economics study estimated that a new treatment saves $2,400 per patient compared to standard care, with a 95% confidence interval of (-$800, $5,600). The hospital administration requires evidence of cost savings with 95% confidence before implementation. Meanwhile, the clinical team argues the treatment should be adopted if there's reasonable possibility of any cost savings. Which interpretation best addresses both perspectives?
Answer: The statistical evidence satisfies the clinical perspective but not the administrative requirement for confident savings
When interpreting confidence intervals in health economics, you need to understand what the interval tells us about statistical certainty versus clinical possibility. A 95% confidence interval gives you a range of plausible values for the true effect, and any value within that range is statistically consistent with your data.
The confidence interval (-$800, $5,600) contains both negative values (indicating potential costs) and positive values (indicating savings). This means we cannot be 95% confident that the treatment saves money - there's a reasonable chance it could actually cost more. However, the interval also shows substantial potential for savings, with most of the range suggesting benefit.
Choice A incorrectly focuses only on the point estimate ($2,400) while ignoring the uncertainty shown by the wide confidence interval. Choice B oversimplifies by completely rejecting implementation, missing the nuanced interpretation needed. Choice C mischaracterizes the situation - a wide confidence interval doesn't make the study "unreliable," just less precise, and this doesn't automatically warrant delay.
Choice D correctly recognizes that different stakeholders can reasonably draw different conclusions from the same statistical evidence. The clinical team's perspective (reasonable possibility of savings) is supported since most of the confidence interval suggests benefit. The administrative requirement (95% confidence of savings) is not met because the interval includes negative values.
Study tip: In health economics questions, always consider how confidence intervals address both statistical certainty and practical decision-making. Different stakeholders may reasonably interpret the same statistical evidence differently based on their risk tolerance and decision criteria.
- A diagnostic test study reports sensitivity of 85% with a 95% confidence interval of (78%, 91%) based on 200 patients with the disease. A clinician wants to know if this test is adequate for screening, requiring sensitivity ≥90%. If the study were repeated with 800 patients with the same true sensitivity, what would most likely happen to the regulatory conclusion?
Answer: The conclusion would likely change against the test since the narrower interval would exclude 90% more definitively
With n=800 (4× larger), the standard error decreases by half, narrowing the CI around 85%. The current CI (78%, 91%) barely includes 90%. With a narrower interval, the upper bound would likely fall below 90%, providing stronger evidence that the test doesn't meet the ≥90% requirement. Choice A incorrectly states larger samples increase CI width. Choice B ignores the precision improvement. Choice D misunderstands that better precision can work against the hypothesis when the point estimate is unfavorable.
- A vaccine efficacy study reports 90% efficacy with a 95% confidence interval of (75%, 96%). The study protocol specified that efficacy ≥80% would be considered clinically acceptable for regulatory approval. Based on this confidence interval, what conclusion is most appropriate for the regulatory decision?
Answer: The evidence is insufficient for a definitive regulatory decision given the uncertainty around the threshold
Since the 95% CI (75%, 96%) straddles the regulatory threshold of 80%, there is substantial uncertainty about whether the true efficacy meets the approval criterion. This creates genuine regulatory uncertainty. Choice A relies only on the point estimate, ignoring uncertainty. Choice B is too conservative. Choice D incorrectly quantifies evidence based on interval proportions.
- A systematic review reports that exercise interventions reduce depression scores by a mean of 4.2 points (95% CI: 2.1, 6.3) on a standardized scale. However, the review notes substantial heterogeneity between studies (I² = 72%). How does this heterogeneity affect the interpretation of the confidence interval?
Answer: The heterogeneity suggests the confidence interval should be wider to reflect additional uncertainty
High heterogeneity (I²=72%) indicates substantial variation between studies beyond sampling error. Even with random-effects models, this suggests the true effect may vary across populations/settings, warranting additional uncertainty beyond what the CI captures. Choice A is too extreme. Choice B assumes fixed-effects was used. Choice D is too confident about random-effects adequacy with such high heterogeneity.
